.Your missionThe Josep Carreras Leukemia Research Institute (IJC) is a comprehensive cancer research center dedicated to researching and promoting innovation in the epidemiological, preventive, clinical, translational and basic aspects of leukemia and other hematological malignancies, with the objective end of finding a cure for these diseases. It was created in 2010, and since then, it has experienced exponential growth.The IJC is also part of the network of Research Centers of Excellence of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC). In addition, the IJC is one of the centers integrated into the accreditation of the Germans Trias i Pujol Research Institute (IGTP) as an Accredited Health Research Institute (IIS) by the Health Institute Charles III (ISCIII).The IJC main headquarters is located within the Can Ruti Biomedical Campus, together with other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six headquarters integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.The contract is subsidized by the project de I+D+i PID2022-140376OB-I00 funded by the Ministry of Science and Innovation, AEI/10.13039/501100011033. Co-financed by the European Regional Development Fund. FEDER A Way of Making Europe.RESEARCH DESCRIPTIONEpigenetic Control of Haematopoiesis Group is working to uncover the molecular mechanisms governing blood cell fate decisions, with a special interest in those leading to the onset of clonal haematopoiesis and myeloid malignancies (AML, MDS, CMML...) during ageing. To address this goal, they are combining transcriptome (by RNA-seq) and epigenomic profiling (by WG(ox)BS-seq, ATAC-seq and ChIP-seq for histone marks) in human and mouse primary blood samples with in-depth molecular studies (by CRISPR/Cas9 (epi)genome editing) in unique cellular models of experimentally induced blood cell fate conversions.Please also visit our group webpage: Epigenetic Control of HaematopoiesisYour profileWHAT WE NEEDWe are seeking a highly motivated, talented researcher assistant to join our team and contribute to this exciting project.General skillsA committed scientist with a competitive scientific record and experience in biology, biomedicine, or related disciplines.A high level of motivation and interest in biomedical research.Good communication skills.Fluent in English